Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the treatment, but they regained control upon restarting it.
Sponsored content is premium paid-for content produced by our Content Studio on behalf of commercial clients. Our newsroom or ...
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...
Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...
Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means ...
Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...
Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to ...
Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...
Blue Cross Blue Shield company Health Care Service Corporation is limiting access for in-office administration of asthma ...
Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 ...